IRIS
CAGNETTA, ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.968
AS - Asia 754
NA - Nord America 623
SA - Sud America 59
AF - Africa 12
OC - Oceania 4
Totale 7.420
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.822
US - Stati Uniti d'America 580
SG - Singapore 272
CN - Cina 173
BD - Bangladesh 133
VN - Vietnam 121
FR - Francia 43
BR - Brasile 31
FI - Finlandia 24
HK - Hong Kong 24
DE - Germania 21
CA - Canada 20
AR - Argentina 16
GB - Regno Unito 12
IQ - Iraq 7
IN - India 6
MX - Messico 6
NL - Olanda 6
CH - Svizzera 5
ES - Italia 5
MA - Marocco 5
UA - Ucraina 5
ID - Indonesia 4
PY - Paraguay 4
AU - Australia 3
EC - Ecuador 3
GR - Grecia 3
IE - Irlanda 3
JM - Giamaica 3
JP - Giappone 3
VE - Venezuela 3
AT - Austria 2
BB - Barbados 2
HN - Honduras 2
KR - Corea 2
NI - Nicaragua 2
PL - Polonia 2
PT - Portogallo 2
RO - Romania 2
SE - Svezia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GT - Guatemala 1
HR - Croazia 1
KE - Kenya 1
LB - Libano 1
LT - Lituania 1
MG - Madagascar 1
MT - Malta 1
PF - Polinesia Francese 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TR - Turchia 1
TW - Taiwan 1
TZ - Tanzania 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 7.420
Salva come PNG Salva come JPEG
Città #
Genova 3.163
Genoa 1.707
Rapallo 484
Vado Ligure 350
Singapore 140
San Jose 129
Ashburn 79
Ho Chi Minh City 41
Lauterbourg 38
Beijing 35
New York 31
Hanoi 25
Helsinki 24
Hong Kong 24
Frankfurt am Main 19
Los Angeles 19
Council Bluffs 16
Santa Clara 16
Phoenix 10
Buffalo 9
Columbus 9
Bordighera 8
Milan 8
Chicago 7
Da Nang 7
Montreal 6
Rome 6
The Dalles 6
Tianjin 6
Turin 6
Dallas 5
Florence 5
Haiphong 5
London 5
Naples 5
Zurich 5
Amsterdam 4
Boardman 4
Washington 4
Biên Hòa 3
Brooklyn 3
Cardiff 3
City of London 3
Denver 3
Kyiv 3
Lansdowne 3
Las Vegas 3
Madrid 3
Memphis 3
Miami 3
Nha Trang 3
Orem 3
Palermo 3
Paris 3
Perugia 3
São Paulo 3
Tokyo 3
Toronto 3
Albany 2
Athens 2
Belo Horizonte 2
Bountiful 2
Boydton 2
Bridgetown 2
Bắc Ninh 2
Can Tho 2
Casablanca 2
Charlotte 2
Chennai 2
Chesapeake 2
Citrus Heights 2
Ciudad del Este 2
Dublin 2
Endicott 2
Greensboro 2
Hewitt 2
Hohenwald 2
Houston 2
Hải Dương 2
Ilion 2
Jacksonville 2
Janesville 2
Lambaré 2
Managua 2
Mattoon 2
Mexico City 2
Milwaukee 2
Nashville 2
Newark 2
Ninh Bình 2
Nuremberg 2
Orlando 2
Ponte dell'Olio 2
Rio de Janeiro 2
Salem 2
San Antonio 2
San Francisco 2
San Juan 2
San Salvador 2
Stockholm 2
Totale 6.611
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 326
APO866 activity in hematologic malignancies: a preclinical in vitro study. 252
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 251
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 250
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 243
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 227
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 211
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 207
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 199
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 196
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 191
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 188
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 182
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 180
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 179
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 177
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 176
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 176
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 171
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 170
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 169
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 167
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 166
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 164
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 159
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 155
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 154
New insights into biology of chronic myeloid leukemia: implications in therapy. 154
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 153
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 152
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 149
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 145
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 144
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 140
MiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 134
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 133
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 129
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 128
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 119
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 112
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 112
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 98
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 79
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma 77
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 67
Partial Inhibition Of Nampt Restores Metabolic Vulnerability And Synergizes With Anti-Myeloma Agents In Multiple Myeloma 19
Totale 7.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.463
article - articoli 23.463
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.926
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022548 21 26 37 69 24 44 30 109 28 47 29 84
2022/2023601 67 67 3 73 97 86 6 37 85 12 64 4
2023/2024391 13 53 14 50 41 80 22 38 10 5 28 37
2024/20251.047 38 64 29 74 96 99 107 230 33 46 106 125
2025/20262.070 234 52 103 207 241 149 273 83 154 184 210 180
2026/2027161 161 0 0 0 0 0 0 0 0 0 0 0
Totale 7.530